The U.S. government has awarded Moderna $590 million to advance the late-stage development of its mRNA bird flu vaccine, as ...

Moderna MRNA provided an update on its financial outlook and pipeline progress at the J.P. Morgan Healthcare Conference. At ...

At the healthcare conference, Moderna lowered expected 2025 revenue to the range of $1.5 billion to $2.5 billion -- down from ...

CDC officials say medical professionals are seeing more patients whose illness cannot be traced back to an infected animal or ...

Is Moderna a no-brainer buy on the sell-off? I wouldn't go that far. Investors should think long and hard about the company's ...

Moderna Inc (MRNA) stock saw a decline, ending the day at $33.76 which represents a decrease of $-1.01 or -2.90% from the prior close of $34.77. The stock opened at $34.75 and touched a low of $33.34 ...

Moderna cut its 2025 sales forecast by $1 billion on Monday, hurt by a slow adoption of its respiratory syncytial virus (RSV) ...

Cases of norovirus infections are surging, but coming up with a way to prevent them has proven to be a challenge.

Shares of Moderna Inc. fell sharply on Monday after the biotech firm projected a steep decline in 2025 revenues, falling ...

Moderna (NASDAQ: MRNA) shareholders have been having a rough time lately. The biotech stock rocketed higher last spring, but ...

Shares of Moderna tumbled Monday after the vaccine maker predicted a steeper-than-expected sales drop in the new year.

Shares of Moderna plunged 20% Monday after the vaccine maker slashed its forecast of full-year 2025 revenue, as sales of its ...